At Merck, we're following the science to tackle some of the world's greatest health threats. Get a glimpse of how we work to improve lives.

Merck's library of assets, photography, video, and contacts for media professionals.

Merck's culture and values all comes back to inventing for live. Merck aspires to be the premier research-intensive biopharmaceutical company in the world

Learn how Merck has created a legacy of inventing medicines and vaccines and become a leading global biopharmaceutical company over the past 130 years.

Nov 14, 2024 · “This agreement adds to Merck’s growing oncology pipeline and we look forward to advancing LM-299 with speed and rigor for patients in need.” Under the agreement, LaNova has granted Merck an exclusive global license to develop, manufacture and commercialize LM-299. LaNova will receive an upfront payment of $588 million.

Dec 31, 2023 · Merck is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products. View the list of products marketed in the U.S.

Explore current job opportunities at Merck. Learn more about careers in Business Support, Clinical, Engineering, Information Technology, Research & Development, Manufacturing and Marketing.

Nov 21, 2022 · RAHWAY, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Imago for $36.00 per share ...

Mar 26, 2024 · Merck offers support to patients who are prescribed WINREVAIR, including information about insurance coverage and help for eligible patients with out-of-pocket costs and co-pay assistance options, through the Merck Access Program.

Nov 5, 2020 · KENILWORTH, N.J. & SAN DIEGO--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and VelosBio Inc. today announced that the companies have entered into a definitive agreement pursuant to which Merck, through a subsidiary, will acquire all outstanding shares of VelosBio for $2.75 billion in cash, subject to ...